- Home
- TEI vs DCTH Comparison
TEI vs DCTH Comparison
Compare TEI & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TEI | DCTH |
|---|---|---|
| Founded | 1993 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.9M | 323.1M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | TEI | DCTH |
|---|---|---|
| Price | $6.27 | $8.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 244.5K | ★ 506.6K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 10.51% | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $29.20 |
| Revenue Next Year | N/A | $29.54 |
| P/E Ratio | ★ N/A | $129.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.78 | $8.12 |
| 52 Week High | $7.00 | $18.23 |
Technical Indicators
Market Signals| Indicator | TEI | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 20.36 | 42.73 |
| Support Level | $6.10 | $8.90 |
| Resistance Level | $6.48 | $10.39 |
| Average True Range (ATR) | 0.08 | 0.39 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 0.67 | 27.38 |
Price Performance
Historical ComparisonAbout TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.